心肌梗死后目标导向维生素D补充对主要不良心血管事件的影响:TARGET-D试验
TARGET-D是一项在心肌梗死患者中比较目标导向维生素D管理与常规治疗的随机试验,纳入630例患者,平均随访4.2年。基线25(OH)D中位数为25 ng/mL,87.0%的患者≤40 ng/mL。目标导向补充维生素D3并滴定至25(OH)D>40-80 ng/mL未能显著降低主要不良心血管事件。
要点
- 心肌梗死患者中25(OH)D不足比例高达87.0%。
- 目标导向维生素D补充未显著降低主要不良心血管事件。
- 维生素D组心肌梗死发生率低于常规治疗组,P=.03。
核心结论
- 目标导向维生素D补充及持续滴定未显著降低心肌梗死患者的主要不良心血管事件。
研究设计与样本
- TARGET-D是一项实效性随机试验,2017年4月至2023年5月入组心肌梗死患者,随机分配至常规治疗或目标导向维生素D管理。
- 共纳入630例受试者,中位年龄63岁,78.1%为男性,平均随访4.2±2.0年。
主要发现
- 主要不良心血管事件在维生素D组为15.7%,常规治疗组为18.4%,HR .85,95%CI .58-1.24,P=.40。
- 次要终点中,维生素D组与常规治疗组的死亡率分别为8.9%与9.2%,HR .98,P=.95。
- 次要终点中,维生素D组与常规治疗组的心肌梗死率分别为3.8%与7.9%,HR .48,P=.03。
- 次要终点中,维生素D组与常规治疗组的心力衰竭住院率分别为4.2%与3.5%,HR 1.21,P=.65。
关键数值与推荐
- 入组患者基线25(OH)D中位数为25 ng/mL,四分位距18-33 ng/mL,87.0%的患者≤40 ng/mL。
- 52.4%的维生素D组患者起始维生素D3剂量为5000 IU,滴定目标为25(OH)D水平>40-80 ng/mL。
临床怎么用
- 心肌梗死患者中维生素D不足普遍,但常规开展目标导向维生素D补充以降低主要不良心血管事件尚缺乏依据。
局限性
- 主要不良心血管事件未达到统计学显著性,P=.40。
- 心肌梗死作为次要终点的显著性结果需谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Many observational studies have reported associations between low serum 25-hydroxyvitamin D [25(OH)D] levels and adverse cardiovascular (CV) outcomes. However, randomized trials have not demonstrated a reduction in CV events with vitamin D supplementation, potentially due to fixed or non-targeted dosing strategies. The aim of this study was to determine if targeted vitamin D management among myocardial infarction (MI) patients reduces CV events. METHODS: TARGET-D is a pragmatic randomized trial, where subjects were randomized to usual care or targeted vitamin D management between April 2017 and May 2023 (average follow-up 4.2 ± 2.0 years). The treatment arm received vitamin D3 supplementation and ongoing titration based on a dosing algorithm to reach and maintain a target 25(OH)D level of >40-80 ng/mL. TARGET-D concluded follow-up on 17 March 2025, when ≥104 primary outcome events (major adverse CV events: composite of death, MI, heart failure hospitalization, and stroke) occurred. RESULTS: Participants (n = 630) had a median age of 63 (interquartile range: 55-70) years and 78.1% were men. Baseline 25(OH)D levels were 25 (interquartile range: 18-33) ng/mL, with 87.0% ≤ 40 ng/mL, and 52.4% began vitamin D3 dosing at 5000 IU. Major adverse CV events did not achieve significance [vitamin D: 15.7% vs usual care: 18.4%; hazard ratio (HR) .85, 95% confidence interval .58-1.24, P = .40]. Among secondary endpoints, outcomes for vitamin D vs usual care were 8.9% vs 9.2% for death (HR .98, P = .95), 3.8% vs 7.9% for MI (HR .48, P = .03), 4.2% vs 3.5% for heart failure hospitalization (HR 1.21, P = .65), and 1.6% vs .9% for stroke (HR 1.69, P = .47). CONCLUSIONS: Prevalence of 25(OH)D insufficiency was high among MI patients. Targeted vitamin D supplementation and ongoing titration did not significantly reduce major adverse CV events.
引用
- May, Le, Anderson, et al. Targeted vitamin D supplementation and major adverse cardiovascular events after myocardial infarction: the TARGET-D trial. Eur Heart J. 2026. PMID: 42702500. doi:10.1093/eurheartj/ehag611
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。